Volanesorsen
Lipoprotein Lipase Deficiency
Akcea Therapeuticsnucleic_acidPhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lipoprotein Lipase Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fenofibrate Novartis Pharmaceuticals | Phase 2 | B |
VUPANORSEN Akcea Therapeutics | Phase 2 | B |
lcq908 Novartis Pharmaceuticals | Phase 2 | B |
Same molecule, other indications
Volanesorsen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →